Icatibant Al (Icatibant)

Icatibant is a selective bradykinin B2 receptor antagonist used to manage hereditary angioedema attacks.

• Acute attacks of hereditary angioedema type I: provides rapid reduction of swelling and pain.
• Acute attacks of hereditary angioedema type II: alleviates edema and improves airway patency.
• Hereditary angioedema (any type): offers prompt symptom control during episodic flare‑ups.

• Icatibant acts as a selective competitive antagonist at the bradykinin B2 receptor. By binding to this receptor, it blocks the actions of bradykinin, preventing vasodilation and increased vascular permeability that underlie the swelling seen in hereditary angioedema. The inhibition of the bradykinin pathway results in rapid resolution of edema during acute attacks.

Icatibant may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Injection site pain: discomfort at the subcutaneous injection site.
• Redness or swelling at injection site: localized erythema.
• Nausea: mild gastrointestinal upset.
• Headache: transient cranial discomfort.
• Dizziness: occasional light‑headedness.
• Flushing: brief warmth or redness of the skin.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Angioedema unrelated to HAE: unexpected swelling in other body parts.
• Hypotension: significant drop in blood pressure.
• Severe injection‑site reactions: necrosis or ulceration.
• Thrombocytopenia: low platelet count observed in rare cases.

Before using Icatibant, consider the following safety measures.

• Pregnancy: safety not established; use only if benefit outweighs potential risk.
• Breastfeeding: unknown excretion; weigh maternal benefit against infant risk.
• Renal impairment: no dosage adjustment required, but monitor for accumulation.
• Concomitant ACE inhibitors or neprilysin inhibitors: may increase bradykinin levels; observe for enhanced edema.
• Hypersensitivity: discontinue immediately if signs of allergic reaction appear.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other agents that influence the bradykinin pathway or cardiovascular function.

Major Interactions (Avoid)

• ACE inhibitors: may potentiate bradykinin‑mediated effects, increasing risk of angioedema.
• Neprilysin inhibitors (e.g., sacubitril): elevate bradykinin levels, heightening adverse‑event potential.
• Other bradykinin‑potentiating drugs: additive risk of swelling.

Moderate Interactions (Monitor Closely)

• Diuretics: may affect blood pressure when combined with hypotensive episodes.
• Antihypertensive agents: monitor for excessive blood pressure reduction.
• Other subcutaneous biologics: assess injection‑site tolerance when administered concurrently.